Amphastar Pharmacueticals Inc

Xencor is a biotechnology company based in Monrovia, California, focused on developing innovative antibody therapeutics, particularly in the realm of bispecific antibodies. Utilizing its proprietary XmAb protein engineering platform, Xencor is advancing a diverse pipeline of drug candidates aimed at treating cancer and other serious diseases, with numerous programs currently in clinical testing. The company's unique approach allows for the creation of highly selective immune-modulators and targeted cancer therapies, enhancing treatment efficacy while improving stability and manufacturability. As an industry leader in bispecific antibodies, Xencor continues to forge partnerships and expand the therapeutic boundaries of antibody drugs. Generated from the website

Cardinal Health was founded in 1971 as Cardinal Foods, a small food distributor in Columbus, Ohio. The company has become a multinational health care industry services provider that helps customers from health care manufacturers to providers of patient care meet challenges. Once it focused entirely on pharmaceutical distribution, Cardinal Health's growth accelerated. Revenues exceeded $1 billion for the first time in 1991. By 1994, Cardinal Health's annual revenues grew to about $6 billion. Since then, Cardinal Health has evolved beyond drug distribution by acquiring leading companies that serve health care manufacturers and providers of patient care. These acquisitions include Pyxis Corporation in automated supply and pharmaceutical dispensing; Owen Healthcare in hospital pharmacy management; Medicine Shoppe International in pharmacy franchising; and Bergen Brunswig in medical-surgical distribution to hospitals and care continuum. Cardinal Health, which is traded on the New York Stock Exchange under the ticker symbol CAH, employs around 55,000 people and has an office on Philadelphia Street in Ontario, Calif.

Synedgen Inc, located in Claremont, California, specializes in innovative technologies aimed at addressing gastrointestinal diseases. The company focuses on research and development, alongside manufacturing, to advance their unique platform in the healthcare sector. With a commitment to improving patient outcomes, Synedgen actively engages in funding and support initiatives to further their mission. Their contributions to the field are reflected in various publications and presentations, underscoring their expertise and innovative approach. Generated from the website